LDS/Medical Tests/MLH3 Gene Mutation Analysis

MLH3 Gene Mutation Analysis

MLH3 (mutL homolog 3) gene located in chromosome 14 at 14q24.3 is a member of the MMR (Mismatch Repair) gene family that are responsible maintaining genomic integrity by correcting base substitution mismatches that may occur during DNA replication.

During DNA replication, 99.9% of errors are detected and corrected by DNA polymerases while remaining base pair substitution errors are detected by the MMR genes. Somatic mutations in MLH3 frequently occur in tumors exhibiting microsatellite instability, and germline mutations have been linked to hereditary nonpolyposis colorectal cancer type 7 (HNPCC7) a subtype of Lynch syndrome. Although18 different mutations of MLH3 have been reported, it is an uncommon cause of Lynch syndrome, accounting for less than 5% of cases.

Pathologic mutations in MMR genes cause Lynch syndrome (previously termed hereditary non-polyposis colorectal cancer, HNPCC). It is an autosomal dominant cancer syndrome involving the colon, rectum, ovaries, endometrium, and stomach. Lynch syndrome is not associated with lung and breast tissues. In the western population, 50% of people with Lynch syndrome develop colorectal cancer by the age of 70. The prevalence of Lynch syndrome is 2 to 5 per 1000 and it accounts for 3%-8% of colorectal cancers. The mutant gene can be inherited in offspring and such individuals have a 90% risk of encountering HNPCC in their lifetime. Detection of mutations involves nuclear amplification, deletion/duplication analysis, and various testing for the recognized mutations.

  • Aids in diagnosing of colorectal cancer and Lynch syndrome
  • Confirms the diagnosis of Hereditary Non-Polyposis Colon Cancer Type 7

Positive: Mutation or pathogenic variants in MLH3 gene.

Negative: No mutation or pathogenic variants in MLH3 gene.

Negative for mutations analysis (no mutations or pathogenic variants detected)

MLH3 deletion/duplication analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) and sequence analysis by Next Generation Sequencing (NGS)/ Massively Parallel Sequencing (MPS).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unacceptable
Carcinoembryonic antigen (CEA), occult blood, Microsatellite instability testing (MSI), germline testing for pathogenic MMR gene variants, biopsy, Immunohistochemistry of tumor tissue, MLH1/MSH2/MSH6/PMS2 gene mutation analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • J Natl Cancer Inst. 2007 Feb 21;99(4):291-9. [PMID: 17312306]
  • Nat Genet. 2000 Jan;24(1):27-35. [PMID: 10615123]
  • Gen Chrom Can. 2008; 47:803-9. [PMID: 18521850]
  • Am Soc Clin Oncol Educ Book. 2018; 38:101-109. [PMID: 30231390].
  • Robert L. Nussbaum RRM, Willard. HF. Thompson & Thompson Genetics in Medicine.8th Edition. 2016; p(187–188).
  • Hartl DL, Cochrane B. Genetics : analysis of genes and genomes. 9th edition. 2017; 829.